Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ramucirumab

- PMLiVE

Cancer immunotherapy: What’s on the horizon?

Old and new therapies

SWITCHED ONcology Patient Experience Focus Group Full Discussion

On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. In...

Havas Lynx

SWITCHED ONcology Patient Experience Focus Group Highlights

On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. "We...

Havas Lynx

SWITCHED ONcology

We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched...

Havas Lynx

18 SWITCHED ONcology: The Big Communication

Matching unprecedented clinical advances in immuno-oncology with transformative communication

Havas Lynx

- PMLiVE

Improving childhood cancer survival rates in developing countries

IntroductionOne of the remarkable success stories in cancer care has been the increase in the long-term survival of children with leukaemia and solid tumours from almost nil to 75-80% cure...

- PMLiVE

Cancer in The Information Age: are we illuminated or inundated?

Is cancer becoming too complicated, too interconnected, for human understanding alone?

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

- PMLiVE

Beyond caring: learning from the unsung advocates in cancer care

Macmillan Cancer Support estimates that there are currently around 1.5 million carers caring for someone who has cancer in the UK. Broadly, carers in and outside cancer contribute around £132...

Lilly appoints Maura Dickler as VP of late phase oncology development

She will join the pharma firm from the Memorial Sloan Kettering Cancer Center

- PMLiVE

Let’s change the conversation about cancer

The changing identity of cancer

- PMLiVE

Amgen and Allergan win first EU approval for Avastin biosimilar

Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links